Sandoz won FDA approval for its Prolia and Xgeva biosimilars—dubbed Jubbonti and Wyost—last March. Aside from being the first U.S.-approved biosimilars to Amgen’s denosumab franchise ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen sells RANKL inhibitor denosumab as Prolia for osteoporosis ... Wyost and Jubbonti have “the same dosage form, route of administration, dosing regimen, and presentation as the respective ...

Amgen stock ... $386 million. Prolia sales popped nearly 12% to $1.11 billion. The company noted nine drugs hit record sales. The best growth came from Blincyto, which treats a form of leukemia.